PharmaTher: Maxim Initiates Coverage With US$1.50 Price Target

PharmaTher Holdings (CSE: PHRM) had its first initiation report that came out on June 28th. Maxim Group initiated coverage on PharmaTher with a U$1.50 price target and a buy rating. Their analyst Jason McCarthy says that the company is “A multi-pronged approach to targeting the psychedelics space.”

PharmaTher is a company that is trying to use ketamine to treat different mental health and neurodegenerative disorders. Additionally, they are combining ketamine with another substance, Betaine, as a specific treatment for depression. McCarthy says ketamine has the potential to be repurposed for Parkinson’s disease. In preclinical and human case studies, ketamine played a dual therapeutic role by treating depression, which occurs in 50% of patients.”

Below you can see PharmaTher’s pipeline.

The company has a few catalysts coming in the next 9 months. The company will start its Phase 2 study to see how ketamine affects Parkinson’s Disease in the third quarter. That will be followed by the readout in the fourth quarter of this year.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

During the fourth quarter, the company will also start its Phase 2 study to see how KETABET affects Depression. McCarthy expects the interim data readout will happen during the same quarter. The last catalyst they believe will come is the topline readout of the KETABET study, which is expected to happen in the first quarter of 2022.

Below you can see PharmaTher expected expenses for 2021 to 2023. McCarthy believes that the expenses will grow due to them initiating Phase 2 studies. He writes that PharmaTher “will likely need multiple equity financings over time to support operations.”

McCarthy concludes the note by state that the company has de-risked its pipeline as a result of targeting the psychedelics space from multiple angles. He comments that future catalysts exist as well, as the firm has two compounds entering phase two studies, with further studies on a microneedle tech platform slated to occur as well.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

This Gold Giant Was a Mess. Now It’s Back! | Barrick Mining Q3 2026 Earnings

Who’s Making Money at $4,000 Gold? | Munich Mining Conference Day 2

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Uber: Consensus Q2 Estimates Point To $3.74 Billion In Revenue

Uber (NYSE: UBER) will be reporting its second quarter financial results after the market close...

Wednesday, August 4, 2021, 02:02:00 PM

Alphabet: Third Quarter 2021 Earnings Preview

Alphabet (NASDAQ: GOOGL) will be reporting its third quarter financial results on October 26th after...

Tuesday, October 26, 2021, 11:17:00 AM

Netflix: BMO Reiterates $700 Price Target Ahead Of Earnings

Netflix (NASDAQ: NFLX) is expected to report its third-quarter financials on today with a call...

Tuesday, October 19, 2021, 03:28:00 PM

Canaccord Reiterates $6.00 Price Target On Valens Company Following Investor Day

This morning, Canaccord Genuity released their takeaway from hosting their first virtual investor day with...

Friday, November 20, 2020, 02:37:00 PM

Peloton: BMO Remains As The Bear Following Q4 Results

At the tail end of August, Peloton Interactive (NASDAQ: PTON) reported its fiscal fourth quarter...

Saturday, September 4, 2021, 01:10:00 PM